Re: Moss: CLINICAL TRIAL OF PANCREATIC ENZYMES: ONE VIEW

[Guest guest]

This trial was nonsense from beginning to

end. Columbia University and the FDA showed a

hostile bias against a study that was intended to

be truth-discovering science. I think this bias

stemmed from a fear that 's enzymes would

outperform the standard chemotherapy regimen,

that is, they had no faith in their own therapies.

's protocol was just as weak as the

conventional protocol. His whole career is based

on the belief that oral pancreatic enzymes (plus

a hodge-podge assemblage of therapies claimed to

be supportive) would provide an effective

non-toxic therapy for pancreatic cancer. I think

that his evidence in favor of his treatment is

very skimpy and he is closed-minded to any

suggestion that enzymes can cause metastasis.

Median survival times was chosen as an endpoint

for the study as both sides probably knew that

any survival is unlikely among both cohorts. No

one comes out as admirable except for NIH. They

were willing to rethink ways to do the study when

patient recruitment into a randomized study

proved to be impossible. At least they seemed to

be genuinely curious -- a great starting place for legitimate science.

>

>

>Pertaining to Dr. , proteolytic enzymes, etc:

>

>[ralphmoss.com]

>

>#408 : Free Weekly Newsletter by Ralph W. Moss, PhD. September 13,

>2009

>

>CLINICAL TRIAL OF PANCREATIC ENZYMES: ONE VIEW

>

>I wanted to share with you an excellent blog from H. Schueler.

>Ken discusses an important article on a trial of pancreatic enzymes that

>was recently published in the Journal of Clinical Oncology....

>

>To read this week's newsletter, please click here:

>

>Cancer Decisions® - Clinical Trial of Pancreatic Enzymes: One View

><http://www.cancerdecisions.com/content/view/232/2/lang,english/>http://www.can\

cerdecisions.com/content/view/232/2/lang,english/